User login
Cetuximab plus FOLFIRI as a first-line therapy in metastatic colon cancer, skin toxicities associated with EGFR inhibitors, and treating hypertension in cancer patients are among the highlights of this month’s podcast, featuring Dr. David Henry, editor-in-chief of Community Oncology.
Cetuximab plus FOLFIRI as a first-line therapy in metastatic colon cancer, skin toxicities associated with EGFR inhibitors, and treating hypertension in cancer patients are among the highlights of this month’s podcast, featuring Dr. David Henry, editor-in-chief of Community Oncology.
Cetuximab plus FOLFIRI as a first-line therapy in metastatic colon cancer, skin toxicities associated with EGFR inhibitors, and treating hypertension in cancer patients are among the highlights of this month’s podcast, featuring Dr. David Henry, editor-in-chief of Community Oncology.